Cygnus Biosciences closes new funding round exceeding 100M yuan

In October 2025, Cygnus Biosciences announced the completion of a new funding round exceeding 100 million yuan, with the transaction successfully finalized. This round was co-led by Shunxi Fund (顺禧基金) and E-Town Capital. The financing not only provides robust momentum for Cygnus's development but also signifies strong market recognition of the company's technological innovation capabilities and growth potential.

Following this funding round, Cygnus will intensify efforts in two core strategic directions: R&D innovation and market expansion. On the R&D front, the company will continue investing in core gene sequencing technologies, building teams with sustainable innovation capabilities, accelerating the launch of sequencing products tailored to diverse application scenarios, and continuously optimizing the performance of existing products to deliver more powerful technological support for both scientific research and clinical applications. In terms of market and commercial capacity building, Cygnus will actively pursue in-depth collaborations with partners to explore and expand broader commercial application scenarios, maximizing the commercial value of gene sequencing technology translation.

Based on its sustained technological advancements, Cygnus Biosciences has successfully launched its S-series and P-series gene sequencers. The S100 sequencer from the S-series has not only obtained EU CE-IVDR certification but also received approval from China's National Medical Products Administration (NMPA) in February 2024 (Registration No. 20243220383), authorizing its use in clinical applications. The S200 gene sequencer, recognized for its fast detection speed, high data quality, and low operating costs, is widely used in pathogen genome sequencing and infectious disease traceability, providing robust technical support for disease control efforts. The P-series sequencing platforms, P1000 and P1000X, deliver a throughput range of 0.3 Tb to 40 Tb per run.

Dr. Chen Zitian, CEO of Cygnus Biosciences, stated: "We sincerely appreciate the forward-looking policy support from governments at all levels and the professional trust of our investment partners in this round. As an innovator deeply committed to the gene sequencing field, we will leverage this capital injection as an accelerator to focus on three key priorities: First, we will continuously increase R&D investment to achieve breakthroughs in critical areas such as the localization of sequencers and the self-sufficiency of reagents and consumables. Second, we will deepen ecosystem collaboration with research institutes and medical institutions to build a complete closed loop from technology development to clinical application. Third, we will promote the accessibility of technology, making gene testing services more affordable and usable for the general public. At Cygnus Biosciences, we firmly believe that only by closely integrating corporate growth with national strategies and public needs can we truly achieve a win-win scenario for both commercial and social value."

Shunxi Fund stated: "Against the backdrop of China's innovation-driven development strategy and accelerated cultivation of new quality productive forces, we have consistently identified gene sequencing technology as a strategic emerging industry for key investment. Cygnus Biosciences stands as one of the few domestic innovative leaders mastering the entire industrial chain of core gene sequencing technologies. Its independently developed sequencing platforms have not only achieved breakthroughs in import substitution but also reached internationally advanced levels in critical metrics such as sequencing speed and cost control, fully demonstrating the innovative capabilities of China's biotech enterprises. This strategic investment is based on our in-depth assessment of Cygnus' technological barriers, R&D team, and business model, while also representing an active alignment with China's 14th Five-Year Plan for Bioeconomy development. We look forward to empowering Cygnus' leapfrog development through capital injection, resource integration, and strategic synergy."

E-Town Capital's investment lead stated: "Amid China's vigorous promotion of strategic emerging industrial clusters and Beijing's accelerated development as an international sci-tech innovation center, we consistently regard the biomedicine industry as a core engine driving high-quality regional economic growth. As a benchmark enterprise cultivated within E-Town's biomedicine sector, Cygnus Biosciences has not only broken foreign technology monopolies with its self-developed domestic gene sequencing platforms but also achieved industrial breakthroughs in critical fields like clinical diagnostics and precision medicine, fully demonstrating the exemplary effect of E-Town's innovation-driven development model."

Looking ahead, Cygnus Biosciences will use this funding round as a new starting point to continue expanding innovation in the gene sequencing field. On one hand, the company will persistently increase R&D investment, continuously optimize the performance of existing products, and accelerate the development and commercialization of new products to maintain its technological leadership. On the other hand, it will actively expand market channels, strengthen brand building, and enhance its visibility and influence in the global market. Simultaneously, Cygnus will deepen collaboration with upstream and downstream partners in the industrial chain to build a more robust industrial ecosystem, contributing to advancements in life sciences and the global healthcare industry.